Promising drug cocktail aims to shrink aggressive nasal tumors before surgery

NCT ID NCT07616141

Not yet recruiting Disease control Sponsor: Eye & ENT Hospital of Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a combination of anlotinib (a targeted therapy) and epirubicin (chemotherapy) before surgery can improve outcomes for people with advanced sinonasal adenoid cystic carcinoma, a rare and aggressive cancer of the nasal cavity and sinuses. About 76 participants will receive two cycles of the drugs, then undergo surgery and radiation. The main goal is to see if this approach increases the 3-year survival without cancer progression compared to historical rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anlotinib (a targeted therapy) plus epirubicin (a chemotherapy drug)
What this could lead to: If successful, this drug combination before surgery could become a new standard treatment for advanced sinonasal adenoid cystic carcinoma, potentially improving survival and reducing the need for disfiguring surgeries.
What could go wrong: This is an early phase II trial with only 76 participants and no comparison group. The combination may cause side effects like fatigue, bleeding, or heart problems, and may not improve outcomes over current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma paranasal sinus adenoid cystic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA

Contacts and locations

Locations

Eye & ENT Hospital of Fudan University

Shanghai, Shanghai Municipality, 200031, China
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266000, China
The Third Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510630, China
Xuanwu Hospital, Capital Medical University

Beijing, Beijing Municipality, 100053, China
Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.